Analyst Reco. Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq Other stock markets 21:00:00 07/05/2024 BST			5-day change	1st Jan Change
15.53 ^USD	+0.52%		+2.78%	-3.18%

04-24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
03-04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Innoviva to $10 From $13, Maintains Underweight Rating	03/03/23	MT
Morgan Stanley Adjusts Price Target on Innoviva to $14 From $13, Maintains Underweight Rating	13/10/22	MT
Goldman Sachs Starts Innoviva at Neutral With $16 Price Target	20/07/22	MT
Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Maintained	15/07/22	MT
Morgan Stanley Raises Innoviva's Price Target to $13 From $12, Maintains Underweight Rating	12/04/22	MT
Morgan Stanley Raises Innoviva's Price Target to $12 From $10, Maintains Underweight Rating	23/02/22	MT
INNOVIVA : Morgan Stanley Adjusts Innoviva PT to $10 From $8, Maintains Underweight Rating	11/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer